Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Guselkumab

Treatment failure: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ruiz DEL Valle V, et al. GUSELKUMAB EFFICACY AND SAFETY ANALYSIS FOR PSA ACCORDING TO BASELINE CHARACTERISTICS AS GENDER, OBESITY OR PREVIOUS TREATMENT IN REAL LIFE AFTER 52 WEEKS. Annals of the Rheumatic Diseases 82 (Suppl. 1): 1789-1790 abstr. AB1119, Jun 2023. Available from: URL: http://doi.org/10.1136/annrheumdis-2023-eular.2055 [abstract] Ruiz DEL Valle V, et al. GUSELKUMAB EFFICACY AND SAFETY ANALYSIS FOR PSA ACCORDING TO BASELINE CHARACTERISTICS AS GENDER, OBESITY OR PREVIOUS TREATMENT IN REAL LIFE AFTER 52 WEEKS. Annals of the Rheumatic Diseases 82 (Suppl. 1): 1789-1790 abstr. AB1119, Jun 2023. Available from: URL: http://​doi.​org/​10.​1136/​annrheumdis-2023-eular.​2055 [abstract]
Metadaten
Titel
Guselkumab
Treatment failure: case report
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47938-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Anakinra

Case report

Aspirin

Case report

Daptomycin

Case report

Lisinopril

Case report

Denosumab